Objectives
Factor XIII is a important key regulator of fibrinolysis and haemostasis. Factor XIII Valine34Leucine (Val34Leu) gene polymorphism has been associated with accelerated fibrin stabilization and increasing resistance to fibrinolysis. QRS duration is associated with poor prognosis in ST elevation myocardial infarction(STEMI).Our aim was to investigate whether factor XIII gene polymorphism on QRS duration in patients with STEMI treated with fibrinolytic therapy.
Methods
A total of 108 patients (87 male, 21 female) with STEMI were included in present study. Electrocardiograph for QRS duration were withdrawn before and after fibrinolytic therapy. QRS duration was measured baseline and at 90 minutes after therapy. Blood samples were obtained from all patients for genetic analysis before fibrinolytic therapy.
Methods
A total of 108 patients (87 male, 21 female) with STEMI were included in present study. Electrocardiograph for QRS duration were withdrawn before and after fibrinolytic therapy. QRS duration was measured baseline and at 90 minutes after therapy. Blood samples were obtained from all patients for genetic analysis before fibrinolytic therapy.
Results
The mean age of the patients were 57,5±9,9 years. Genotype distribution of the Factor XIII polymorphism was as follows: Val/Val in 67 (62 %) patients, Val/Leu in 37 (34,3%) patients and Leu/Leu in 4 (3,7%) patients. Forty-one of those patients (38%) had Leu carrier.Table was shown between genotype groups and baseline parameters.The patients with Val/Val genotype showed longer QRS duration than patients with Val/Leu or Leu/Leu genotype at the baseline( 90±13msn vs 88±12 msn vs 82±12msn, p:0,461 respectively).Whereas, the patients with Val/Leu genotype showed longer QRS duration than patients with Val/Val or Leu/Leu genotype at the 90 minutes after therapy ( 93±14msn vs 86±14 msn vs 90±21msn, p:0,041 respectively). However, magnitude of the QRS duration prolongation was higher in patients with carrying the Leu allele than no carrying the Leu allele at the 90 minutes after therapy ( 93±14msn vs 86±14 msn, p:0,013 respectively). In addition, the Leu allele carriers had a reduced ejection fraction(EF) ( 43,9±5,6 vs 47,1±8,8 p:0,04 respectively).
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
